OncoImmunology (Dec 2022)

Ecto-calreticulin expression in multiple myeloma correlates with a failed anti-tumoral immune response and bad prognosis

  • Alfonso Serrano Del Valle,
  • Manuel Beltrán-Visiedo,
  • Victoria de Poo-Rodríguez,
  • Nelia Jiménez-Alduán,
  • Gemma Azaceta,
  • Rosana Díez,
  • Beatriz Martínez-Lázaro,
  • Isabel Izquierdo,
  • Luis Palomera,
  • Javier Naval,
  • Alberto Anel,
  • Isabel Marzo

DOI
https://doi.org/10.1080/2162402X.2022.2141973
Journal volume & issue
Vol. 11, no. 1

Abstract

Read online

Immunogenic cell death (ICD) has been proposed to be a crucial process for antitumor immunosurveillance. ICD is characterized by the exposure and emission of Damage Associated Molecular Patterns (DAMP), including calreticulin (CRT). A positive correlation between CRT exposure or total expression and improved anticancer immunosurveillance has been found in certain cancers, usually accompanied by favorable patient prognosis. In the present study, we sought to evaluate CRT levels in the plasma membrane of CD38+ bone marrow mononuclear cells (BMMCs) isolated from 71 patients with varying degrees of multiple myeloma (MM) disease and examine the possible relationship between basal CRT exposure and the bone marrow immune microenvironment, as well as its connection with different clinical markers. Data show that increased levels of cell surface-CRT were associated with more aggressive clinical features and with worse clinical prognosis in MM. High CRT expression in MM cells was associated with increased infiltration of NK cells, CD8+ T lymphocytes and dendritic cells (DC), indicative of an active anti-tumoral immune response, but also with a significantly higher presence of immunosuppressive Treg cells and increased expression of PD-L1 in myeloma cells.

Keywords